Profiling Peptides for Mcl-1 Sensitivity Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for profiling the functionality of anti-apoptotic Bcl-2 family proteins in cancer cells are complex, inefficient, and prone to variation due to the need for cell permeabilization with digitonin, making them unsuitable for decentralized use in clinical settings and lacking in accuracy and cost-effectiveness.
Innovation Solution
Development of profiling peptides with a cellular uptake moiety and an Mcl-1 binding domain, specifically with sequences as shown in SEQ ID NO:1 with 0-8 modifications, which can cross cell membranes and bind to Mcl-1, allowing for the detection of mitochondrial integrity changes in cancer cells without the need for digitonin, enabling more accurate and reproducible assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If flow cytometry with cell surface marker labeling and gating is used to measure BH3 profiling response, then measurement precision is improved, but device complexity and ease of operation deteriorate
Solution Approach 1:
The patent extracts the essential measurement function from complex flow cytometry systems by using a fluorescence microplate reader that directly measures mitochondrial membrane potential changes in response to BH3 peptide treatment. This eliminates the need for cell surface marker labeling, antibody conjugation, and complex gating procedures, retaining measurement precision while removing unnecessary complexity
Solution Approach 2:
The patent introduces JC-1 fluorescent dye as an intermediary that directly reports mitochondrial membrane potential changes. This intermediary provides a simple, direct readout of BH3 profiling results without requiring complex cell isolation or marker-based identification, thereby simplifying the overall measurement system while maintaining accuracy
2Measurement precision
If cell separation techniques and purification steps are used to isolate malignant population, then measurement precision is improved, but productivity and ease of operation deteriorate
Solution Approach 1:
The patent applies a universal assay protocol using fluorescence microplate reader that can directly measure BH3 profiling in mixed cell populations without requiring separate purification steps for malignant cells. The assay simultaneously processes multiple samples in high-throughput format, achieving both population specificity and high productivity through its multi-functional design
Solution Approach 2:
The patent changes the measurement parameter from cell surface marker detection to mitochondrial membrane potential detection using JC-1 dye. This parameter change allows direct measurement in intact cells within mixed populations, eliminating the need for time-consuming cell separation while maintaining the ability to specifically assess cancer cell response to BH3 peptides
3Reliability
If digitonin permeabilization is used to allow BH3 peptide entry, then reliability of apoptosis induction is improved, but manufacturing precision and ease of operation deteriorate
Solution Approach 1:
The patent employs cell-permeable BH3 peptide analogs that can spontaneously cross cell membranes without requiring digitonin permeabilization. The peptides are designed with intrinsic membrane-permeability properties, allowing them to self-deliver into cells and induce apoptosis reliably, thereby eliminating the need for precise digitonin concentration control and associated operational complexities
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These profiling peptides facilitate the prediction of cancer cell sensitivity to therapeutic agents by determining Mcl-1 dependency percentages, allowing for targeted treatment approaches and improving the accuracy and cost-effectiveness of cancer treatment profiling.
Implementation Method 1
a profiling peptide comprising a cellular uptake moiety and an Mcl-1 binding domain
Implementation Method 2
an Mcl-1 binding domain having the sequence of SEQ ID NO:1 with 0-8 modifications
Implementation Method 3
detecting a change in mitochondrial integrity of the cancer cell
Data Source
AI summary
The present disclosure is generally directed to profiling peptides, compositions, and kits, as well as methods of use thereof. The profiling peptides comprise an Mcl-1 binding domain, and optionally a cellular uptake moiety. The methods of using such profiling peptides include predicting sensitivity of a cancer, selecting a treatment, treating a cancer, producing a sensitivity profile, and the like.